MDS Nordion Appoints Kenneth Newport to its Board of Directors
September 03 2010 - 6:00AM
PR Newswire (Canada)
OTTAWA, Sept. 3 /CNW/ -- OTTAWA, Sept. 3 /CNW/ - MDS Nordion, a
leader in providing products and services for the global health
sciences market, today announced that Kenneth Newport of Ottawa,
Canada has been appointed to its Board of Directors. "We welcome
Ken and look forward to the unique contribution he will bring to
the Board," said William Anderson, Chairman, MDS Inc. "With his
varied background in the accounting, financial services and life
sciences industries, we expect Ken's fresh perspective and
entrepreneurial spirit will be valuable in strategically navigating
Nordion's business into the future." "MDS Nordion has emerged from
its recent strategic repositioning as a strong leader in its core
markets," said Mr. Newport. "With its established core competencies
and its focus on innovation, I believe the company is
well-positioned for long-term growth. I look forward to helping
maximize this potential along with my fellow directors and the
Nordion management team." Mr. Newport served as Senior Vice
President and Executive Committee member at PRA International Inc.
for three years until his retirement in 2005. In the mid-nineties
he was co-founder and President of CroMedica Inc., a clinical
trials contract research organization which was sold to PRA
International in 2002. Mr. Newport was also a founding member of
Global Biomedical Capital Corporation, Zelos Therapeutics Inc.,
Prime Trials Inc. and other life science organizations. He is a
member of the Institute of Corporate Directors and serves on the
corporate boards of The Opmedic Group, Jennerex Inc, and Medgenesis
Therapeutics Inc. About MDS Inc. MDS Inc. (TSX: MDS; NYSE: MDZ) is
a global health science company that provides market-leading
products and services used for the prevention, diagnosis and
treatment of disease. We are a leading provider of innovative
technologies for use in medical imaging and radiotherapeutics, and
sterilization technologies benefiting the lives of millions of
people in more than 65 countries around the world. Our products and
services are used daily by pharmaceutical and biotechnology
companies, medical-device manufacturers, hospitals, clinics and
research laboratories. MDS has more than 700 highly skilled people
in five locations. Find out more at www.mdsnordion.com. MEDIA:
Tamra Benjamin, (613) 592-3400 x1022, tamra.benjamin@mdsinc.com;
INVESTORS: Ana Raman, (613) 595-4580, investor.relations@mdsinc.com
Copyright
Mds (NYSE:MDZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mds (NYSE:MDZ)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Mds (New York Stock Exchange): 0 recent articles
More Mds News Articles